Grant E. Blouse

Novo Nordisk Park
Malov, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Correlation of antigen expression with epigenetic modifications after rAAV delivery of a human factor IX variant in mice and rhesus macaques.

Correlation of antigen expression with epigenetic modifications after rAAV delivery of a human factor IX variant in mice and rhesus macaques.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: January 22, 2024

Subcutaneous Marzeptacog Alfa (Activated) for On-Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors.

Subcutaneous Marzeptacog Alfa (Activated) for On-Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors.

Journal: Clinical pharmacology and therapeutics

Published: October 14, 2023

Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients.

Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients.

Journal: Advances in therapy

Published: May 02, 2023

Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy.

Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy.

Journal: CPT: pharmacometrics & systems pharmacology

Published: October 16, 2022

Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug.

Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug.

Journal: CPT: pharmacometrics & systems pharmacology

Published: June 02, 2022

Gene therapy for hemophilia B using CB 2679d-GT: a novel factor IX variant with higher potency than factor IX Padua.

Gene therapy for hemophilia B using CB 2679d-GT: a novel factor IX variant with higher potency than factor IX Padua.

Journal: Blood

Published: March 27, 2020

Factor VIII with a 237 amino acid B-domain has an extended half-life in F8-knockout mice.

Factor VIII with a 237 amino acid B-domain has an extended half-life in F8-knockout mice.

Journal: Journal of thrombosis and haemostasis : JTH

Published: April 12, 2018

Releasing the brakes in coagulation Factor IXa by co-operative maturation of the substrate-binding site.

Releasing the brakes in coagulation Factor IXa by co-operative maturation of the substrate-binding site.

Journal: The Biochemical journal

Published: April 13, 2016

Showing 1-8 of 8

Last Updated: 09/26/2026